The company, AstraZeneca, revealed that it intends to produce the next generation of the AstraZeneca, Oxford vaccine, for the Corona virus to meet the mutated variants by the fall, according to Reuters.
A senior executive at the British pharmaceutical company said today, Wednesday, that AstraZeneca and the University of Oxford are aiming to produce the next generation of Corona vaccines that will protect against variants as soon as possible in the fall.
Asked when AstraZeneca could produce a next-generation vaccine to deal with the new variants, Maine Pangalos, head of AstraZeneca research, said as soon as possible.
"We are working very hard and we are already talking not only about the variants that we have to do in the laboratories, but also about the clinical studies that we need to conduct," he said in a briefing to the media, adding, "We are very aiming to try to have a vaccine thing ready to fight the new variants by the fall." , this year.
Professor Andrew Pollard, director of the Oxford Vaccine Group, said that partners are close to having data on the effectiveness of the Corona vaccine in the elderly.
British researchers have suggested that the Oxford-AstraZeneca vaccine significantly reduces virus transmission, rather than simply preventing accidental infection.
The rate of positive PCR tests was cut in half after two doses, according to the preliminary results of researchers at the University of Oxford.
Comments
Post a Comment